--- title: "Miriam González — Precision Oncology for an Ultra-Rare Tumor" canonical_url: "https://helpmiriam.com/en" last_updated: "2026-06-10T22:50:18.869Z" meta: description: "Miriam has an ultra-rare metastatic breast cancer that protocols don't cover. Support the precision tests that could change her treatment." "og:description": "BC-NED with FGFR1 ×13 and SSTR2+. Support the advanced molecular rebiopsy that could change her treatment." "og:title": "Miriam González — Precision Oncology for an Ultra-Rare Tumor" "twitter:description": "BC-NED with FGFR1 ×13 and SSTR2+. Support the advanced molecular rebiopsy." "twitter:title": "Miriam González — Precision Oncology for an Ultra-Rare Tumor" --- Metastatic breast cancer · Ultra-rare molecular profile # A rare cancer, *a real opportunity*. ![Portrait of Miriam González](https://helpmiriam.com/.netlify/images?w=840&h=840&fm=webp&url=%2Fimg%2Fmiriam-avatar.webp) _Engineer · Communicator_ ****Miriam, 35,**** has a tumor with two sides that Spanish protocols don't account for. The tests she needs to treat it aren't covered by public healthcare. This site exists to fund them. [Support Miriam](https://gofund.me/3e25cae99) Every euro funds clinical research applied to her case. [See the science](https://helpmiriam.com/en/science) Open the full molecular profile in The science. Already supported by **970** people · featured in El País [**Latest**· updated 11 days ago~~A new scan opens another door~~](https://helpmiriam.com/en/timeline#lo-ultimo) **€38,166** raised so far **970** people have contributed **5+** specialists in 3 countries **80%** neuroendocrine differentiation The story ## A diagnosis that fit no protocol. At 33, Miriam was diagnosed with a metastatic breast cancer so rare it is seen in ****fewer than 1 in 1,000 cases****. The standard treatment isn't enough: it has to be designed around her specific tumor. [~~Source: SEER population analysis · Transl. Cancer Res., 2023~~](https://doi.org/10.21037/tcr-23-368) [Get to know Miriam (soon) ](https://helpmiriam.com/en/story) In her own words > «**My tumor has two sides —the breast side and the neuroendocrine one— and the key is to treat both at once, not just one.**» *— Miriam González. May 2026.* Clinical gap ## What Spanish protocols don't cover, we cover. *Spanish protocols only account for half of the tumor's biology: they're built for standard HR+ breast cancer, and Miriam's is not.* In practice: hormonal treatment addresses the tumor's side but leaves its component untreated. Confirming and targeting it requires molecular rebiopsy and international expert review — tests public healthcare doesn't cover for such a rare case. Tap or hover the highlighted words and markers to see what they mean. ### **What exists vs. what is missing** What the protocols cover What is missing and not covered Initial diagnosis and routine follow-up Updated multi-omic analysis of the tumor (genomics, transcriptomics, proteomics) Standard hormonal treatment Consultation with specialists in uncommon profiles Symptom and toxicity management Access to clinical trials designed for her type of case Reports and clinical documentation Tests that allow treatment to be adjusted to what the tumor is doing now *Full technical analysis in The science. The essential point: a measurable gap exists between the treatment she receives and the one her biology requires.* Where this is heading ## The goal is an N-of-1 trial designed for this tumor's exact biology. An trial is a clinical trial built for a single patient: treatment is designed around her tumor's actual profile, not an average protocol. That makes it possible to combine drugs to target its two sides at once — the luminal (breast) one and the possible neuroendocrine one. **The advantages of reaching that trial:**- Treatment is adjusted to the real profile of the tumor, not to a protocol designed for the majority. - Drugs suited to each part of the tumor can be applied simultaneously. - Every result obtained contributes evidence for other patients with similar profiles. - Miriam stops depending on a single protocol that does not answer her case. In one line, for anyone who wants the detail: ✱Those with “?” are hypotheses with partial evidence, pending confirmation. Full analysis in The science. [See the full molecular profile](https://helpmiriam.com/en/science) Open clinical documentation. Updated in 2026. Where the money goes · Radical transparency ## The tumor evolves. The strategy has to evolve with it. The tumor evolves under treatment pressure. New resistance mutations appear (ESR1 D538G, RB1) and new targets emerge (SSTR2+). Without periodic molecular rebiopsy, clinical decisions are made ****blind****. Every euro is assigned to a concrete line item and documented on the Expenses page. **The money goes to:**- Molecular tests and diagnostics (rebiopsy, sequencing, panels). - Consultations and second opinions with international specialists. - Medication and treatments not covered. - AI tools, case management and outreach. [See the full breakdown ](https://helpmiriam.com/en/expenses) Three ways to contribute · Pick yours ## Not every way to help costs money. Each action counts differently. 01 ### **Level 1 · Share (no cost)** Getting the case in front of whoever can move it forward —in oncology, research or among patients— is often the difference between finding a therapeutic target and not finding one. Share the site with whoever can move the case forward. 02 ### **Level 2 · Read the science (cognitive commitment)** Understand the full molecular profile, the active biological hypotheses and the compatible clinical trials. Open, reviewed documentation. [Read the molecular profile](https://helpmiriam.com/en/science) No sign-up, no paywall. 03 ### **Level 3 · Fund (financial commitment)** Every euro funds research applied to the case: deep sequencing, molecular rebiopsy, international second opinions, N-of-1 trial. [Support Miriam](https://gofund.me/3e25cae99) Secure payment. Receipt available. 100% to Miriam's case. High-impact profiles **Are you a doctor, researcher or journalist?** There's a direct door for you. [Doctor / researcher](https://helpmiriam.com/en/collaborate#revision-clinica) [ Press / media](https://helpmiriam.com/en/collaborate#alcance) Campaign status · Real time ## **Every euro brings the next priority molecular analysis closer.** In the press [El País(opens in a new tab)](https://elpais.com/tecnologia/2026-04-23/asi-usa-una-paciente-con-cancer-metastasico-la-ia-para-entender-su-enfermedad-cual-es-el-mejor-metodo-para-hablar-de-salud-con-chatbots.html) [La Opinión de Murcia(opens in a new tab)](https://www.laopiniondemurcia.es/comunidad/2026/05/30/paciente-murciana-aguarda-nuevo-tratamiento-130816775.html) [La 7(opens in a new tab)](https://www.instagram.com/p/DZDT2hIAMPU/?hl=es) [Are you a journalist? Get in touch ](https://helpmiriam.com/en/contact)